AIM: To determine the effectiveness of theophyllines in real clinical practice on moderate to severe exacerbations. METHODS: A cohort of 36,492 chronic obstructive pulmonary disease (COPD) patients aged > or =50 years was reconstructed from the health administrative databases of the province of Quebec, Canada, between 1 January 1995 and 31 December 2002 to compare users of theophyllines with users of inhaled corticosteroids (ICS) and users of long-acting beta(2)-agonists (LABA) on their rate of moderate to severe COPD exacerbations. RESULTS: Users of theophyllines were found to be less likely than users of LABA [crude rates 84 vs. 91 per 100 patient-years, adjusted rate ratio (RR) 0.89, 95% confidence interval (CI) 0.84, 0.95] and users of theophyllines plus ICS were found to be less likely than users of LABA plus ICS (crude rates 114 vs. 112 per 100 patient-years, adjusted RR 0.89, 95% CI 0.87, 0.92) to have moderate to severe COPD exacerbations. Users of theophyllines were found to be more likely than users of ICS to have a COPD exacerbation (crude rates 84 vs. 77 per 100 patient-years, adjusted RR 1.07, 95% CI 1.04, 1.10), and this association was even stronger among patients who had at least three exacerbations in the year prior to cohort entry (crude rates 273 vs. 213 per 100 patient-years, adjusted RR 1.28, 95% CI 1.19, 1.38). CONCLUSION: The use of theophyllines was found to be associated with a reduction in the rate of COPD exacerbations among all COPD patients, but to be less effective than ICS among patients with frequent exacerbations.
AIM: To determine the effectiveness of theophyllines in real clinical practice on moderate to severe exacerbations. METHODS: A cohort of 36,492 chronic obstructive pulmonary disease (COPD) patients aged > or =50 years was reconstructed from the health administrative databases of the province of Quebec, Canada, between 1 January 1995 and 31 December 2002 to compare users of theophyllines with users of inhaled corticosteroids (ICS) and users of long-acting beta(2)-agonists (LABA) on their rate of moderate to severe COPD exacerbations. RESULTS: Users of theophyllines were found to be less likely than users of LABA [crude rates 84 vs. 91 per 100 patient-years, adjusted rate ratio (RR) 0.89, 95% confidence interval (CI) 0.84, 0.95] and users of theophyllines plus ICS were found to be less likely than users of LABA plus ICS (crude rates 114 vs. 112 per 100 patient-years, adjusted RR 0.89, 95% CI 0.87, 0.92) to have moderate to severe COPD exacerbations. Users of theophyllines were found to be more likely than users of ICS to have a COPD exacerbation (crude rates 84 vs. 77 per 100 patient-years, adjusted RR 1.07, 95% CI 1.04, 1.10), and this association was even stronger among patients who had at least three exacerbations in the year prior to cohort entry (crude rates 273 vs. 213 per 100 patient-years, adjusted RR 1.28, 95% CI 1.19, 1.38). CONCLUSION: The use of theophyllines was found to be associated with a reduction in the rate of COPD exacerbations among all COPDpatients, but to be less effective than ICS among patients with frequent exacerbations.
Authors: Andrea Rossi; Peter Kristufek; Bernard E Levine; Moira H Thomson; Denise Till; John Kottakis; Giovanni Della Cioppa Journal: Chest Date: 2002-04 Impact factor: 9.410
Authors: Denis E O'Donnell; Shawn Aaron; Jean Bourbeau; Paul Hernandez; Darcy Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Roger Goldstein; Rick Hodder; Francois Maltais; Jeremy Road Journal: Can Respir J Date: 2003 May-Jun Impact factor: 2.409
Authors: Michael Mehring; Antonius Schneider; Johannes Fexer; Ewan Donnachie; Manfred Keller; Frank Hofmann; Stefan Wagenpfeil Journal: Dtsch Arztebl Int Date: 2014-09-19 Impact factor: 5.594
Authors: Samuel Louie; Amir A Zeki; Michael Schivo; Andrew L Chan; Ken Y Yoneda; Mark Avdalovic; Brian M Morrissey; Timothy E Albertson Journal: Expert Rev Clin Pharmacol Date: 2013-03 Impact factor: 5.045
Authors: Johannes Fexer; Ewan Donnachie; Antonius Schneider; Stefan Wagenpfeil; Manfred Keller; Frank Hofmann; Michael Mehring Journal: Dtsch Arztebl Int Date: 2014-04-25 Impact factor: 5.594
Authors: Graham Devereux; Seonaidh Cotton; Peter Barnes; Andrew Briggs; Graham Burns; Rekha Chaudhuri; Henry Chrystyn; Lisa Davies; Anthony De Soyza; Shona Fielding; Simon Gompertz; John Haughney; Amanda J Lee; Kirsty McCormack; Gladys McPherson; Alyn Morice; John Norrie; Anita Sullivan; Andrew Wilson; David Price Journal: Trials Date: 2015-06-10 Impact factor: 2.279
Authors: Rupasri Mandal; Raul Cano; Cindy D Davis; David Hayashi; Scott A Jackson; Christina M Jones; Johanna W Lampe; Marie E Latulippe; Nancy J Lin; Katrice A Lippa; Paulina Piotrowski; Sandra M Da Silva; Kelly S Swanson; David S Wishart Journal: Metabolomics Date: 2020-11-08 Impact factor: 4.290